Based in Trinity College Dublin, Pharmatrin is developing a novel class of therapeutics known as indane dimers. The target
therapeutic areas are organ transplant rejection and autoimmune diseases.
Investment: €1.5 million ($1.8 million)
Source: A consortium of investors that includes Growcorp, the Campus Companies Venture Capital Fund, and the Wellcome Trust. Other
investors include Catalyst Biomedica, Trinity Venture Capital, Enterprise Ireland, and Trinity College Dublin.
STOKES BIO LIMITED
Stokes Bio develops microfluidics-based diagnostic systems for the genetic diagnosis of cancer. Childhood leukemia is the
initial target disease, around which the microfluidics-based platform technology is developed. The Company is working in close
collaboration with the Childhood Cancer Center of St Bartholomew's Hospital London, and the oncology department of the Regional
Investment: €1 million ($1.17 million)
Source: The Cork-based venture capital firm, Kernel Capital Partners.
TriMed RESEARCH INC.
TriMed Research Ltd is an Irish-American biotechnology company based on technology spun out of the University of Nebraska
Medical Center. TriMed is focused on therapeutic anti-infective products applied to the prevention of life-threatening infections
of low birth weight infants and in immunosuppressed and oncology patients. The technology also has applications in the functional
food and veterinary fields.
Investment: €5.0 million ($5.85 million)
Source: Seroba BioVentures and Inventages (Switzerland).